Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NADINA: Neoadjuvant Ipilimumab + Nivolumab vs Adjuvant Nivolumab in Stage III Melanoma
NCT04949113Phase 3Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of ipilimumab in melanoma, sponsored by Netherlands Cancer Institute. Started Jul 2021; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04949113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04949113.